{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:33:24Z","timestamp":1783971204843,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer-associated thrombosis is a frequent complication of cancer; however, little evidence is available regarding the association between cancer history and coronary artery stent thrombosis (ST). We aimed to investigate the relationship between cancer history and second-generation drug-eluting stent thrombosis (G2-ST).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From the REAL-ST (Retrospective Multicenter Registry of ST After First- and Second-Generation Drug-Eluting Stent Implantation) registry, this study evaluated 1265 patients (G2- ST cases, <jats:italic>n<\/jats:italic>\u2009=\u2009253; controls, <jats:italic>n<\/jats:italic>\u2009=\u20091012) with cancer-related information available.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence of patients with cancer history was higher (12.3% vs. 8.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.065), and that of currently diagnosed and currently treated cancer was significantly higher in ST cases than controls (3.6% vs. 1.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.021; 3.2% vs. 1.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.037, respectively). Multivariable logistic regression analysis revealed that cancer history was associated with late ST (odds ratio [OR]: 2.80, 95% confidence intervals [CI]: 0.92\u20138.55, <jats:italic>p<\/jats:italic>\u2009=\u20090.071) and very late ST (OR: 2.40, 95% CI: 1.02-5.65, <jats:italic>p<\/jats:italic>\u2009=\u20090.046), but not with early ST (OR: 1.01, 95% CI: 0.51-2.00, <jats:italic>p<\/jats:italic>\u2009=\u20090.97). During the median follow-up period of 872\u00a0days after the index ST events, patients with cancer history showed a higher mortality than those without, among both ST cases (hazard ratio [HR]: 1.93, 95% CI: 1.06-3.51, <jats:italic>p<\/jats:italic>\u2009=\u20090.031) and controls (HR: 1.93, 95% CI: 1.09-3.40, <jats:italic>p<\/jats:italic>\u2009=\u20090.023).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A post hoc analysis of REAL-ST registry revealed that patients with G2-ST had a higher prevalence of currently diagnosed and currently treated cancer. Notably, cancer history was associated with the occurrence of late and very late ST, but not with early ST.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12959-023-00503-5","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T07:02:52Z","timestamp":1684911772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between cancer history and second-generation drug-eluting stent thrombosis: insights from the REAL-ST registry"],"prefix":"10.1186","volume":"21","author":[{"given":"Tomoyo","family":"Hamana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kuramitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Natsuaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the REAL-ST Registry Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"503_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.108.799403","volume":"119","author":"JW van Werkum","year":"2009","unstructured":"van Werkum JW, Heestermans AA, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009;119:828\u201334.","journal-title":"Circulation"},{"key":"503_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/jjco\/hyv165","volume":"46","author":"S Ikushima","year":"2016","unstructured":"Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K. Trousseau\u2019s syndrome: cancer-associated thrombosis. Jpn J Clin Oncol. 2016;46:204\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"503_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","volume":"10","author":"NB Abdol Razak","year":"2018","unstructured":"Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10:380.","journal-title":"Cancers (Basel)"},{"key":"503_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3324\/haematol.2018.197814","volume":"103","author":"V De Stefano","year":"2018","unstructured":"De Stefano V. Arterial thrombosis and cancer: the neglected side of the coin of Trousseau syndrome. Haematologica. 2018;103:1419\u201321.","journal-title":"Haematologica"},{"key":"503_CR5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104\u201314.","journal-title":"Circulation"},{"key":"503_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/2048872617706501","volume":"7","author":"M Iannaccone","year":"2018","unstructured":"Iannaccone M, D\u2019Ascenzo F, Vadal\u00e0 P, Wilton SB, Noussan P, Colombo F, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care. 2018;7:631\u20138.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"503_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/2047487314566998","volume":"23","author":"RC van Kruijsdijk","year":"2016","unstructured":"van Kruijsdijk RC, van der Graaf Y, Koffijberg H, de Borst GJ, Nathoe HM, Jaap Kappelle L, et al. Cause-specific mortality and years of life lost in patients with different manifestations of vascular disease. Eur J Prev Cardiol. 2016;23:160\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"503_CR8","doi-asserted-by":"publisher","first-page":"e007822","DOI":"10.1161\/CIRCINTERVENTIONS.119.007822","volume":"12","author":"S Kuramitsu","year":"2019","unstructured":"Kuramitsu S, Ohya M, Shinozaki T, Otake H, Horie K, Kawamoto H, et al. Risk factors and long-term clinical outcomes of second-generation drug-eluting stent thrombosis. Circ Cardiovasc Interv. 2019;12:e007822.","journal-title":"Circ Cardiovasc Interv"},{"key":"503_CR9","doi-asserted-by":"publisher","first-page":"e018972","DOI":"10.1161\/JAHA.120.018972","volume":"10","author":"S Enomoto","year":"2021","unstructured":"Enomoto S, Kuramitsu S, Shinozaki T, Ohya M, Otake H, Yamanaka F, et al. Risk factors and outcomes of recurrent drug-eluting stent thrombosis: insights from the REAL-ST registry. J Am Heart Assoc. 2021;10:e018972.","journal-title":"J Am Heart Assoc"},{"key":"503_CR10","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"503_CR11","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"503_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMp030086","volume":"349","author":"RL Bick","year":"2003","unstructured":"Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349:109\u201311.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"503_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.bjc.6605599","volume":"102","author":"S Noble","year":"2010","unstructured":"Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(Suppl 1):2\u20139.","journal-title":"Br J Cancer"},{"key":"503_CR14","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","volume":"103","author":"E Grilz","year":"2018","unstructured":"Grilz E, K\u00f6nigsbr\u00fcgge O, Posch F, Schmidinger M, Pirker R, Lang IM, et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica. 2018;103:1549\u201356.","journal-title":"Haematologica"},{"key":"503_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/eurheartj\/ehaa1032","volume":"42","author":"CS Kwok","year":"2021","unstructured":"Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, et al. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J. 2021;42:1019\u201334.","journal-title":"Eur Heart J"},{"key":"503_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/ehjqcco\/qcx047","volume":"4","author":"N Tabata","year":"2018","unstructured":"Tabata N, Sueta D, Yamamoto E, Takashio S, Arima Y, Araki S, et al. Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes. 2018;4:290\u2013300.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"503_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12928-021-00754-x","volume":"36","author":"S Kuramitsu","year":"2021","unstructured":"Kuramitsu S, Sonoda S, Ando K, Otake H, Natsuaki M, Anai R, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther. 2021;36:158\u201368.","journal-title":"Cardiovasc Interv Ther"},{"key":"503_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jcin.2020.12.005","volume":"14","author":"KH Chau","year":"2021","unstructured":"Chau KH, Kirtane AJ, Easterwood RM, Redfors B, Zhang Z, Witzenbichler B, et al. Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: analysis from ADAPT-DES. JACC Cardiovasc Interv. 2021;14:417\u201327.","journal-title":"JACC Cardiovasc Interv"},{"key":"503_CR19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","volume":"53","author":"JW van Werkum","year":"2009","unstructured":"van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J Am Coll Cardiol. 2009;53:1399\u2013409.","journal-title":"J Am Coll Cardiol"},{"key":"503_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","volume":"3","author":"O Leiva","year":"2021","unstructured":"Leiva O, AbdelHameid D, Connors JM, Cannon CP, Bhatt DL. common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis: jacc: cardiooncology State-of-the-art review. JACC CardioOncol. 2021;3:619\u201334.","journal-title":"JACC CardioOncol"},{"key":"503_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.beha.2008.12.009","volume":"22","author":"A Falanga","year":"2009","unstructured":"Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22:49\u201360.","journal-title":"Best Pract Res Clin Haematol"},{"key":"503_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-016-0502-4","volume":"18","author":"K Marmagkiolis","year":"2016","unstructured":"Marmagkiolis K, Finch W, Tsitlakidou D, Josephs T, Iliescu C, Best JF, et al. Radiation toxicity to the cardiovascular system. Curr Oncol Rep. 2016;18:15.","journal-title":"Curr Oncol Rep"},{"key":"503_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0049-3848(00)00294-2","volume":"99","author":"GI Togna","year":"2000","unstructured":"Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503\u20139.","journal-title":"Thromb Res"},{"key":"503_CR24","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","volume":"133","author":"J Herrmann","year":"2016","unstructured":"Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue. Circulation. 2016;133:1272\u201389.","journal-title":"Circulation"},{"key":"503_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jjcc.2011.07.004","volume":"58","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa G. Stent thrombosis of drug eluting stent: pathological perspective. J Cardiol. 2011;58:84\u201391.","journal-title":"J Cardiol"},{"key":"503_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.thromres.2019.03.016","volume":"178","author":"I Mazin","year":"2019","unstructured":"Mazin I, Paul G, Asher E. Neoatherosclerosis - From basic concept to clinical implication. Thromb Res. 2019;178:12\u20136.","journal-title":"Thromb Res"},{"key":"503_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jcin.2021.03.049","volume":"14","author":"W Guo","year":"2021","unstructured":"Guo W, Fan X, Lewis BR, Johnson MP, Rihal CS, Lerman A, et al. Cancer patients have a higher risk of thrombotic and ischemic events after percutaneous coronary intervention. JACC Cardiovasc Interv. 2021;14:1094\u2013105.","journal-title":"JACC Cardiovasc Interv"},{"key":"503_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","volume":"3","author":"L Gervaso","year":"2021","unstructured":"Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with cancer: JACC: cardioOncology State-of-the-art review. JACC CardioOncol. 2021;3:173\u201390.","journal-title":"JACC CardioOncol"},{"key":"503_CR29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927\u201374.","journal-title":"Blood Adv"},{"key":"503_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","volume":"140","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140:240\u201361.","journal-title":"Circulation"},{"key":"503_CR31","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","volume":"40","author":"JE Potts","year":"2019","unstructured":"Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J. 2019;40:1790\u2013800.","journal-title":"Eur Heart J"},{"key":"503_CR32","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jama.2022.1820","volume":"327","author":"MJ Holmberg","year":"2022","unstructured":"Holmberg MJ, Andersen LW. Collider Bias. JAMA. 2022;327:1282\u20133.","journal-title":"JAMA"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00503-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-023-00503-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00503-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T07:04:49Z","timestamp":1684911889000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-023-00503-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s12959-023-00503-5","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"24 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Kokura Memorial Hospital with the reference number 17091551.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}